Key Points
- Vicki Sato sold 22,000 shares of Vir Biotechnology at an average price of $9.51 on March 2 for about $209,220, leaving her with 1,122,391 shares and a 1.92% decline in ownership.
- Vir beat quarterly estimates with EPS of ($0.31) and revenue of $64.07M (up 417.8% YoY) but remains unprofitable with a very negative net margin and ROE, while analysts have raised ratings and set a consensus target of $19.89 (consensus: "Moderate Buy").
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $9.51, for a total value of $209,220.00. Following the sale, the director owned 1,122,391 shares of the company's stock, valued at approximately $10,673,938.41. This trade represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Vir Biotechnology Trading Down 4.6%
NASDAQ VIR opened at $8.91 on Wednesday. The stock has a market cap of $1.24 billion, a PE ratio of -2.82 and a beta of 1.65. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $10.94. The company's 50-day moving average price is $7.14 and its 200-day moving average price is $6.16.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million during the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm's revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) EPS. As a group, sell-side analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.
Analyst Upgrades and Downgrades
VIR has been the topic of several research reports. Wall Street Zen upgraded Vir Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday. Barclays upped their price objective on shares of Vir Biotechnology from $26.00 to $30.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 24th. Raymond James Financial raised shares of Vir Biotechnology from an "outperform" rating to a "strong-buy" rating and set a $19.00 target price on the stock in a research report on Tuesday, February 24th. Leerink Partners restated an "outperform" rating and issued a $20.00 price target on shares of Vir Biotechnology in a report on Thursday, February 26th. Finally, Morgan Stanley increased their price objective on shares of Vir Biotechnology from $20.00 to $24.00 and gave the company an "overweight" rating in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $19.89.
Check Out Our Latest Report on Vir Biotechnology
Hedge Funds Weigh In On Vir Biotechnology
A number of large investors have recently added to or reduced their stakes in VIR. ARCH Venture Management LLC purchased a new position in shares of Vir Biotechnology in the 2nd quarter worth approximately $65,100,000. Aberdeen Group plc boosted its stake in Vir Biotechnology by 51.6% in the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company's stock valued at $8,715,000 after acquiring an additional 519,374 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in Vir Biotechnology by 812.7% in the second quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company's stock valued at $2,938,000 after acquiring an additional 519,107 shares in the last quarter. Corton Capital Inc. purchased a new position in Vir Biotechnology in the second quarter worth $114,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Vir Biotechnology during the second quarter worth $63,000. 65.32% of the stock is currently owned by institutional investors.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
